SoFi Raises 2026 Outlook as Quarterly Revenue Hits Record $1.385 Billion
Key Facts
SoFi said on October 27 that net revenue was $1.385 billion in the third quarter ended September 30, 2026, up 44% year over year, and raised its full-year outlook. Kiniksa said in results for the same period that revenue was $286.0 million, compared with $180.9 million a year earlier, alongside an update to its sales outlook for ARCALYST. EL7 data showed SoFi shares closed at $14.46 on October 26, while Kiniksa shares closed at $72.98. Investing.com reported that SoFi shares rose 6.22% in premarket trading on October 27 after the results and raised outlook were announced. It also reported that Kiniksa shares climbed 17.84% to $86 in premarket trading, surpassing their 52-week high of $84.06. These documented moves differ from intraday percentages and prices cited in a Benzinga summary, and do not represent confirmed closing prices.
SoFi's third-quarter net income under generally accepted accounting principles was $240.989 million, compared with $139.392 million in the same period of 2025, while diluted earnings per share rose to $0.18 from $0.11. On an adjusted basis, the company reported revenue of $1.371 billion, up 44% year over year, and adjusted earnings before interest, taxes, depreciation and amortization of $469.818 million, an increase of 70%. Adjusted net income was also $242.986 million. The figures reflect expansion in revenue and earnings during the quarter, alongside growth in users and products. The company added a record 1.2 million members during the quarter, along with 2.2 million products. Total members reached 17.1 million, up 35% year over year, while the number of products rose to 26.7 million, a 44% increase.
SoFi raised its 2026 outlook to adjusted revenue of $5.04 billion and adjusted earnings before interest, taxes, depreciation and amortization of $1.66 billion. The company also provided its first outlook for 2027, forecasting adjusted revenue of $6.4 billion, adjusted earnings of $2.24 billion and earnings per share of $0.90. These estimates set out a numerical path for the next two years alongside the quarterly results, while the available materials did not provide further detail on the factors underpinning the 2027 outlook. The premarket share gain was linked to the results and raised outlook, according to Investing.com. The quarterly data show simultaneous growth in adjusted revenue, earnings, membership and products. Measuring the stock's performance during the session remains distinct from its previous closing price of $14.46.
At Kiniksa, operating expenses rose to $231.7 million in the third quarter, compared with $156.8 million in the same period of 2025, alongside an increase in revenue to $286.0 million from $180.9 million. Chief Executive Sanj Patel said, "Strong commercial execution led to increased adoption by patients and physicians," adding that ARCALYST generated revenue of $286.0 million during the quarter. The company said about 23% of a group of 14,000 patients with multiple annual episodes were receiving treatment with the drug at quarter-end. The number of prescribers who had written ARCALYST prescriptions for recurrent pericarditis had also exceeded 5,450 since its launch. These figures provide commercial context for revenue growth, but do not establish that the results alone caused the share move. The stock's previous close was $72.98 on October 26.
Kiniksa said it had $568.8 million in cash, cash equivalents and short-term investments on September 30, 2026, and no debt. In drug development, the company continues to enroll and dose patients in the pivotal Phase 3 trial of KPL-387. It expects trial data in the second half of 2027. It also aims to begin a first-in-human Phase 1 trial of KPL-1161 by the end of 2026. These are the next milestones the company identified for its research pipeline, while its report combines growth in ARCALYST sales with progress in clinical trial programs.